Shanghai, China - MicroPort^® CardioFlow Medtech Corporation (hereinafter referred to as MicroPort^® CardioFlow, stock code: 02160.HK) recently announced that following Alwide^® Plus Balloon Catheter, the second generation of balloon catheter, Its self-developed new generation Transcatheter Aortic Valve Implantation (" TAVI ") product VitaFlow Liberty^® Transcatheter Aortic Valve and Retrivable Delivery System (" VitaFlow Liberty^® ") has received marketing approval from the Saudi Food and Drug Administration (SFDA).

As China's first and the world's only electric retrievable transcatheter aortic valve system, VitaFlow Liberty^® was approved for marketing by the NMPA in 2021. Since then, it has been successively launched in multiple overseas countries and obtained the EU CE-MDR certification in 2024, becoming the first domestically developed TAVI system approved by EU.  To date, the VitaFlow^® series TAVI solution along with its accessory - the Alwide^® series Balloon Catheter, has successfully covered nearly 700 core hospitals in 10 countries and regions, treating over 10,000 patients with aortic valve diseases worldwide.

Saudi Arabia, one of the fastest-growing major economies globally and the largest economy in the Middle East, possesses tremendous potential in the high-end medical device market. The approval of VitaFlow Liberty^® in Saudi Arabia will accelerate its internationalization process and benefit more patients with structural heart diseases worldwide.